A drug intended to help the heart took an unexpected turn after men participating in clinical trials began sharing an unusual experience. What followed would change the treatment of erectile dysfunction and make Viagra one of the most recognizable medicines in the world.
Ghanaian urologist Dr. Samuel Gepi-Attee has offered a fascinating account of how the research that led to Viagra changed direction after trial participants noticed an effect the researchers had not initially set out to investigate.
In an interview with Kafui Dey, the retired consultant urologist revealed that sildenafil citrate, the drug later marketed as Viagra, was originally being developed for its potential to help people with heart-related conditions.
Asked whether the drug was initially intended to help the heart, Dr. Gepi-Attee confirmed that this was indeed the case.
“Its original design was as a cardiac vessel dilator,” he explained.
He went on to clarify what that meant, saying the drug was being explored for conditions such as angina, a type of chest pain associated with reduced blood flow to the heart.
“You know, for things like angina and so on,” he said, as he explained that dilation meant opening up the blood vessels.
But while the drug was being investigated for this purpose, something unexpected began happening among the men participating in the trials.
Dr. Gepi-Attee said some of the participants started comparing experiences and discussing the effects they were noticing after taking the medication.
“Whilst it was being explored for this, some of the candidates for whom the trial was going on started discussing with others,” he recalled.
The conversations among the participants soon caught attention.
“Wasn’t this interesting? But I got this effect, and then between themselves they were saying, ‘Yeah, I got it too,’” he recounted.
Their observations pointed to an effect on erectile function.
“So it became clear that it had an effect on erectile function,” Dr. Gepi-Attee said.
The discovery was particularly significant because the participants were taking the medication orally. They were not receiving injections.
Asked whether the drug was administered as a pill or an injection, he replied: “No, that was a pill. It was a pill. They were getting erections.”
The unexpected development prompted an important change in the direction of the research.
Dr. Gepi-Attee suggested that had the participants not discussed their experiences, the researchers might not have recognised the significance of what was happening.
“Imagine if they hadn’t discussed these things around. You wouldn’t have known, you researchers,” Kafui Dey remarked.
Dr. Gepi-Attee responded that this was, indeed, how the discovery began.
“It isn’t anything which… but anyway, that is how it started. That’s how it started,” he said.
He explained that once the organizer of the trial noticed the unexpected effect, the research was redirected towards erectile dysfunction.
“Once the organizer of the trial noticed it, he said we should target erectile function,” he revealed.
The testing did not stop. Instead, its objective changed.
“So we continued the testing, but now with the destination of it changed to erectile dysfunction,” he said.
That shift would eventually lead to the development of a treatment that transformed the options available to men experiencing difficulties with erections.
INSIDE THE TRIALS
Beyond recounting how the research changed direction, Dr. Gepi-Attee also offered a rare glimpse into what the clinical trials involved.
He explained that the work required researchers to monitor the amount of medication in participants’ bodies and assess how they responded to it.
“It involves taking blood samples and things to be sure that the right levels of the drug were being obtained in the patient,” he said.
The research also involved tests designed to assess the drug’s effect under different conditions.
“And then doing various stimulant tests, some of them visually expressive tests, to see what difference it made when you did the test after taking the tablets and when you did the test without taking the tablets,” he explained.
When Kafui Dey sought clarification on the nature of the visual tests, Dr. Gepi-Attee confirmed that they involved sexually stimulating videos.
The purpose was to observe whether the visual stimulation produced a response and compare the results with those obtained without it.
“You are now doing the testing to be able to report objectively,” he explained.
Researchers also assessed the proportion of participants who experienced erections without visual stimulation, allowing them to compare the results from the different tests.
The participants were recruited from people already on a clinic waiting list.
“Generally, what you did was you held a waiting list of people who wanted to come to the clinic for you to give them whatever treatment options you had,” he said.
The researchers then recruited participants from that list to take part in the study.
“So we recruited people from that list to be able to arrange them to test them systematically,” he added.
A RESEARCHER’S CONTRIBUTION
For Dr. Gepi-Attee, the experience was more than an interesting medical development. It was an opportunity to contribute to research in an area where treatment options had been limited.
He disclosed that he was among the researchers involved in taking sildenafil through its clinical phase.
“I am glad that I was one of the original researchers that took it through the clinical phase,” he said.
He acknowledged that the number of researchers involved was relatively small and considered his participation a significant opportunity.
“There couldn’t have been that many people, and I was one of them,” he said.
Reflecting on the significance of the work, he described it as unique and ultimately successful.
“I think it was unique and ultimately successful,” he added.
He explained that the research was particularly relevant to his professional interests because he was already working in andrology, the branch of medicine concerned with male reproductive and sexual health.
“Remember, I was working in andrology already,” he said.
“It was an area that we were not very successful as urologists in treating.”
The emergence of sildenafil therefore offered a promising new possibility.
“So there’s a drug now which carries the promise of stimulating natural erections, and I was one of those who was asked to work on it,” he said.
“So yes, I liked that opportunity.”